Email this article Splenic marginal zone lymphoma: management specifics. Clinical observation
- Authors: Zeynalova P.A.1,2, Davydov M.M.1,2, Ryabukhina Y.E.1, Shogenov M.S.1, Zhukov A.G.1, Nigmatullina E.R.3
-
Affiliations:
- Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
- I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
- MGIMO-MED Medical University
- Issue: Vol 4, No 3 (2024)
- Pages: 93-98
- Section: RARE AND COMPLEX CLINICAL SITUATIONS: DIAGNOSIS AND SELECTION OF TREATMENT TACTICS
- Published: 24.09.2024
- URL: https://mdonco.abvpress.ru/jour/article/view/143
- DOI: https://doi.org/10.17650/2782-3202-2024-4-3-93-98
- ID: 143
Cite item
Full Text
Abstract
Despite having common histological and immunophenotypic characteristics with other marginal zone lymphomas, splenic marginal zone lymphoma (SMZL) has distinctive clinical and biological features. The main indications for therapy of this disease (of primarily indolent progression) are progressive splenomegaly and/or progressive cytopenia. Current clinical management guidelines do not conclusively point to advantages of one certain therapy, and there is no universal algorithm of management of patients with newly diagnosed SMZL manifesting through progressive splenomegaly. Therefore, determination of indications for surgical treatment is an important problem. A clinical observation of a female patient with newly diagnosed advanced SMZL is presented. Due to progressive splenomegaly and hypersplenism symptoms, the patient underwent splenectomy. Personalized multidisciplinary approach allowed to relieve hypersplenism symptoms as quickly as possible, and the absence of postoperative complications with indolent disease progression significantly increased the patient’s quality of life and allowed to continue dynamic observation.
About the authors
P. A. Zeynalova
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
ORCID iD: 0000-0003-1564-424X
Department of Oncology
143081; 111 1st Uspenskoe Shosse; Moscow region; Lapino; 119991; Bld. 2, 8 Trubetskaya St.; Moscow
Russian FederationM. M. Davydov
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
ORCID iD: 0000-0001-5038-9307
Department of Oncology
143081; 111 1st Uspenskoe Shosse; Moscow region; Lapino; 119991; Bld. 2, 8 Trubetskaya St.; Moscow
Russian FederationYu. E. Ryabukhina
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Author for correspondence.
Email: gemonk.yur@mail.ru
ORCID iD: 0000-0001-8443-8816
Yulia Evgenyevna Ryabukhina
143081; 111 1st Uspenskoe Shosse; Moscow region; Lapino
Russian FederationM. S. Shogenov
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
143081; 111 1st Uspenskoe Shosse; Moscow region; Lapino
Russian FederationA. G. Zhukov
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
ORCID iD: 0000-0001-5353-8857
143081; 111 1st Uspenskoe Shosse; Moscow region; Lapino
Russian FederationE. R. Nigmatullina
MGIMO-MED Medical University
143007; 3 Novosportivnaya St.; Moscow region; Odintsovo
Russian FederationReferences
- WHO Classification of Tumours Editorial Board. Haematolymphoid tumours. WHO classification of tumours series. 5th edn. Vol. 11. France, Lyon: IARC, 2022. Available at: https://tumourclassification.iarc.who.int/chapters/63
- Alaggio R., Amador C., Anagnostopoulos I. et al. The 5th edition of the World Health Organization Classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 2022;36(7):1720–48. doi: 10.1038/s41375-022-01620-2
- Zucca E., Arcaini L., Buske C. et al. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020;31(1):17–29. doi: 10.1016/j.annonc.2019.10.010
- Santos T.S.D., Tavares R.S., Farias D.L.C. Splenic marginal zone lymphoma : a literature review of diagnostic and therapeutic challenges. Rev Bras Hematol Hemoter. 2017;39(2):146–54. doi: 10.1016/j.bjhh.2016.09.014
- Lymphoma of the marginal zone. Clinical recommendations. 2023. (In Russ.).
- Thieblemont C., Davi F., Noguera M.E. et al. Splenic marginal zone lymphoma: current knowledge and future directions. Oncology (Williston Park) 2012;26(2):194–202.
- Olszewski A.J. Survival outcomes with and without splenectomy in splenic marginal zone lymphoma. Am J Hematol 2012;87(11):E119–22. doi: 10.1002/ajh.23314
- Olszewski A.J., Ali S. Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma. Ann Hematol 2014;93(3):449–58. doi: 10.1007/s00277-013-1900-4
- Kalpadakis C., Pangalis G.A., Angelopoulou M.K., Vassilakopoulos T.P. Treatment of splenic marginal zone lymphoma. Best Pract Res Clin Haematol 2017;30(1–2):139–48. doi: 10.1016/j.beha.2016.07.004
- Bonfiglio F., Bruscaggin A., Guidetti F. et al. Genetic and phenotypic attributes of splenic marginal zone lymphoma. Blood 2022;139(5):732–47. doi: 10.1182/blood.2021012386
- Fallah J., Olszewski A.J. Diagnostic and therapeutic splenectomy for splenic lymphomas: analysis of the National Cancer Data Base. Hematology 2019;24(1):378–86.
Supplementary files
